KIORA PHARMACEUTICALS, INC. Research and Development Expense
KIORA PHARMACEUTICALS, INC. (KPRX) reported Research and Development Expense of $2.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-07
- KIORA PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-06-30 was $2.08M, a 19.82% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-03-31 was $2.12M, a 16.12% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-12-31 was $2.93M, a 52.16% increase year-over-year.
- KIORA PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-09-30 was $2.73M, a 24.94% increase year-over-year.
- KIORA PHARMACEUTICALS, INC. research and development expense for fiscal 2025 was $10.78M, a 37.47% increase from fiscal 2024.
- KIORA PHARMACEUTICALS, INC. research and development expense for fiscal 2024 was $7.84M, a 94.74% increase from fiscal 2023.
- KIORA PHARMACEUTICALS, INC. research and development expense for fiscal 2023 was $4.03M, a 16.76% increase from fiscal 2022.
- KIORA PHARMACEUTICALS, INC. research and development expense for fiscal 2022 was $3.45M, a 35.54% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.08M 10-Q · filed 2026-08-07 | $4.20M 10-Q · filed 2026-08-07 | $7.13M derived: sum of 3 quarters · filed 2026-08-07 | $9.86M derived: sum of 4 quarters · filed 2026-08-07 | |||
| 2026-03-31 | $2.12M 10-Q · filed 2026-05-08 | $5.05M derived: sum of 2 quarters · filed 2026-05-08 | $7.78M derived: sum of 3 quarters · filed 2026-05-08 | $10.37M derived: sum of 4 quarters · filed 2026-08-07 | |||
| 2025-12-31 | $2.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $5.66M derived: sum of 2 quarters · filed 2026-03-25 | $8.25M derived: sum of 3 quarters · filed 2026-08-07 | $10.78M 10-K · filed 2026-03-25 | |||
| 2025-09-30 | $2.73M 10-Q · filed 2025-11-07 | $5.32M derived: sum of 2 quarters · filed 2026-08-07 | $7.85M 10-Q · filed 2025-11-07 | $9.78M derived: sum of 4 quarters · filed 2026-08-07 | |||
| 2025-06-30 | $2.59M 10-Q · filed 2026-08-07 | $5.12M 10-Q · filed 2026-08-07 | $7.05M derived: sum of 3 quarters · filed 2026-08-07 | $9.23M derived: sum of 4 quarters · filed 2026-08-07 | |||
| 2025-03-31 | $2.53M 10-Q · filed 2026-05-08 | $4.46M derived: sum of 2 quarters · filed 2026-05-08 | $6.64M derived: sum of 3 quarters · filed 2026-05-08 | $8.69M derived: sum of 4 quarters · filed 2026-05-08 | |||
| 2024-12-31 | $1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $4.11M derived: sum of 2 quarters · filed 2026-03-25 | $6.16M derived: sum of 3 quarters · filed 2026-03-25 | $7.84M 10-K · filed 2026-03-25 | |||
| 2024-09-30 | $2.18M 10-Q · filed 2025-11-07 | $1.32M 10-Q · filed 2024-11-08 | $4.23M derived: sum of 2 quarters · filed 2025-11-07 | $5.92M 10-Q · filed 2025-11-07 | $3.72M 10-Q · filed 2024-11-08 | $7.03M derived: sum of 4 quarters · filed 2025-11-07 | |
| 2024-06-30 | $2.05M 10-Q · filed 2025-08-08 | $906.68K 10-Q · filed 2024-08-09 | $3.73M 10-Q · filed 2025-08-08 | $2.40M 10-Q · filed 2024-08-09 | $4.84M derived: sum of 3 quarters · filed 2025-08-08 | $5.93M derived: sum of 4 quarters · filed 2025-08-08 | |
| 2024-03-31 | $1.68M 10-Q · filed 2025-05-09 | $1.49M 10-Q · filed 2024-05-10 | $2.80M derived: sum of 2 quarters · filed 2025-05-09 | $3.88M derived: sum of 3 quarters · filed 2025-05-09 | $5.27M derived: sum of 4 quarters · filed 2025-05-09 | ||
| 2023-12-31 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $2.20M derived: sum of 2 quarters · filed 2025-03-25 | $3.59M derived: sum of 3 quarters · filed 2025-03-25 | $4.03M 10-K · filed 2025-03-25 | |||
| 2023-09-30 | $1.09M 10-Q · filed 2024-11-08 | $2.48M derived: sum of 2 quarters · filed 2024-11-08 | $2.92M 10-Q · filed 2024-11-08 | $3.76M derived: sum of 4 quarters · filed 2024-11-08 | |||
| 2023-06-30 | $1.39M 10-Q · filed 2024-08-09 | $1.83M 10-Q · filed 2024-08-09 | $2.67M derived: sum of 3 quarters · filed 2024-08-09 | $4.00M derived: sum of 4 quarters · filed 2024-08-09 | |||
| 2023-03-31 | $438.28K 10-Q · filed 2024-05-10 | $1.28M derived: sum of 2 quarters · filed 2024-05-10 | $2.61M derived: sum of 3 quarters · filed 2024-05-10 | $3.18M derived: sum of 4 quarters · filed 2024-05-10 | |||
| 2022-12-31 | $841.62K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $2.17M derived: sum of 2 quarters · filed 2024-03-25 | $2.74M derived: sum of 3 quarters · filed 2024-03-25 | $3.45M 10-K · filed 2024-03-25 | |||
| 2022-09-30 | $1.33M 10-Q · filed 2023-11-09 | $1.90M derived: sum of 2 quarters · filed 2023-11-09 | $2.61M 10-Q · filed 2023-11-09 | $3.61M derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2022-06-30 | $567.23K 10-Q · filed 2023-08-08 | $1.28M 10-Q · filed 2023-08-08 | $2.28M derived: sum of 3 quarters · filed 2023-08-08 | $3.91M derived: sum of 4 quarters · filed 2023-08-08 | |||
| 2022-03-31 | $707.93K 10-Q · filed 2023-05-09 | $1.71M derived: sum of 2 quarters · filed 2023-05-09 | $3.34M derived: sum of 3 quarters · filed 2023-05-09 | $4.78M derived: sum of 4 quarters · filed 2023-05-09 | |||
| 2021-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $2.63M derived: sum of 2 quarters · filed 2023-03-23 | $4.07M derived: sum of 3 quarters · filed 2023-03-23 | $5.35M 10-K · filed 2023-03-23 | |||
| 2021-09-30 | $1.63M 10-Q · filed 2022-11-09 | $3.07M derived: sum of 2 quarters · filed 2022-11-09 | $4.35M 10-Q · filed 2022-11-09 | $5.36M derived: sum of 4 quarters · filed 2022-11-09 | |||
| 2021-06-30 | $1.44M 10-Q · filed 2022-08-12 | $2.72M 10-Q · filed 2022-08-12 | $3.73M derived: sum of 3 quarters · filed 2022-08-12 | $4.72M derived: sum of 4 quarters · filed 2022-08-12 | |||
| 2021-03-31 | $1.28M 10-Q · filed 2022-07-08 | $2.29M derived: sum of 2 quarters · filed 2022-07-08 | $3.28M derived: sum of 3 quarters · filed 2022-07-08 | $3.91M derived: sum of 4 quarters · filed 2022-07-08 | |||
| 2020-12-31 | $1.01M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-07-07 | $2.00M derived: sum of 2 quarters · filed 2022-07-07 | $2.63M derived: sum of 3 quarters · filed 2022-07-07 | $3.57M 10-K/A · filed 2022-07-07 | |||
| 2020-09-30 | $985.88K 10-Q · filed 2021-11-15 | $1.62M derived: sum of 2 quarters · filed 2021-11-15 | $2.56M 10-Q · filed 2021-11-15 | $4.05M derived: sum of 4 quarters · filed 2021-11-15 | |||
| 2020-06-30 | $631.11K 10-Q · filed 2021-08-12 | $1.57M 10-Q · filed 2021-08-12 | $3.07M derived: sum of 3 quarters · filed 2021-08-12 | $5.47M derived: sum of 4 quarters · filed 2021-08-12 | |||
| 2020-03-31 | $938.04K 10-Q · filed 2021-05-12 | $2.44M derived: sum of 2 quarters · filed 2021-05-12 | $4.84M derived: sum of 3 quarters · filed 2021-05-12 | $5.61M derived: sum of 4 quarters · filed 2021-05-12 | |||
| 2019-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $3.90M derived: sum of 2 quarters · filed 2021-03-25 | $4.67M derived: sum of 3 quarters · filed 2021-03-25 | $5.39M 10-K · filed 2021-03-25 | |||
| 2019-09-30 | $2.41M 10-Q · filed 2020-11-09 | $3.17M derived: sum of 2 quarters · filed 2020-11-09 | $3.89M 10-Q · filed 2020-11-09 | $5.33M derived: sum of 4 quarters · filed 2020-11-09 | |||
| 2019-06-30 | $763.90K 10-Q · filed 2020-08-06 | $1.49M 10-Q · filed 2020-08-06 | $2.92M derived: sum of 3 quarters · filed 2020-08-06 | $5.18M derived: sum of 4 quarters · filed 2020-08-06 | |||
| 2019-03-31 | $721.48K 10-Q · filed 2020-05-06 | $2.16M derived: sum of 2 quarters · filed 2020-05-06 | $4.42M derived: sum of 3 quarters · filed 2020-05-06 | $6.26M derived: sum of 4 quarters · filed 2020-05-06 | |||
| 2018-12-31 | $1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-04 | $3.70M derived: sum of 2 quarters · filed 2020-03-04 | $5.53M derived: sum of 3 quarters · filed 2020-03-04 | $8.06M 10-K · filed 2020-03-04 | |||
| 2018-09-30 | $2.26M 10-Q · filed 2019-11-07 | $4.10M derived: sum of 2 quarters · filed 2019-11-07 | $6.62M 10-Q · filed 2019-11-07 | $9.70M derived: sum of 4 quarters · filed 2019-11-07 | |||
| 2018-06-30 | $1.84M 10-Q · filed 2019-08-08 | $4.36M 10-Q · filed 2019-08-08 | $7.44M derived: sum of 3 quarters · filed 2019-08-08 | $10.61M derived: sum of 4 quarters · filed 2019-08-08 | |||
| 2018-03-31 | $2.52M 10-Q · filed 2019-05-08 | $5.60M derived: sum of 2 quarters · filed 2019-05-08 | $8.77M derived: sum of 3 quarters · filed 2019-05-08 | $11.04M derived: sum of 4 quarters · filed 2019-05-08 | |||
| 2017-12-31 | $3.08M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $6.25M derived: sum of 2 quarters · filed 2019-03-01 | $8.52M derived: sum of 3 quarters · filed 2019-03-01 | $10.33M 10-K · filed 2019-03-01 | |||
| 2017-09-30 | $3.18M 10-Q · filed 2018-11-13 | $5.44M derived: sum of 2 quarters · filed 2018-11-13 | $7.25M 10-Q · filed 2018-11-13 | $9.83M derived: sum of 4 quarters · filed 2018-11-13 | |||
| 2017-06-30 | $2.26M 10-Q · filed 2018-08-03 | $4.08M 10-Q · filed 2018-08-03 | $6.65M derived: sum of 3 quarters · filed 2018-08-03 | $9.10M derived: sum of 4 quarters · filed 2018-08-03 | |||
| 2017-03-31 | $1.81M 10-Q · filed 2018-05-11 | $4.39M derived: sum of 2 quarters · filed 2018-05-11 | $6.84M derived: sum of 3 quarters · filed 2018-05-11 | $9.32M derived: sum of 4 quarters · filed 2018-05-11 | |||
| 2016-12-31 | $2.58M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-02 | $5.03M derived: sum of 2 quarters · filed 2018-03-02 | $7.51M derived: sum of 3 quarters · filed 2018-03-02 | $8.42M 10-K · filed 2018-03-02 | |||
| 2016-09-30 | $2.45M 10-Q · filed 2017-11-14 | $4.93M derived: sum of 2 quarters · filed 2017-11-14 | $5.84M 10-Q · filed 2017-11-14 | $7.23M derived: sum of 4 quarters · filed 2017-11-14 | |||
| 2016-06-30 | $2.48M 10-Q · filed 2017-08-04 | $3.40M 10-Q · filed 2017-08-04 | $4.78M derived: sum of 3 quarters · filed 2017-08-04 | $5.19M derived: sum of 4 quarters · filed 2017-08-04 | |||
| 2016-03-31 | $913.97K 10-Q · filed 2017-05-05 | $2.30M derived: sum of 2 quarters · filed 2017-05-05 | $2.71M derived: sum of 3 quarters · filed 2017-05-05 | $3.31M derived: sum of 4 quarters · filed 2017-05-05 | |||
| 2015-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $1.79M derived: sum of 2 quarters · filed 2017-02-23 | $2.40M derived: sum of 3 quarters · filed 2017-02-23 | $2.72M 10-K · filed 2017-02-23 | |||
| 2015-09-30 | $407.57K 10-Q · filed 2016-11-01 | $1.01M derived: sum of 2 quarters · filed 2016-11-01 | $1.33M 10-Q · filed 2016-11-01 | $1.44M derived: sum of 4 quarters · filed 2016-11-01 | |||
| 2015-06-30 | $604.11K 10-Q · filed 2016-08-10 | $925.55K 10-Q · filed 2016-08-10 | $1.03M derived: sum of 3 quarters · filed 2016-08-10 | $1.15M derived: sum of 4 quarters · filed 2016-08-10 | |||
| 2015-03-31 | $321.44K 10-Q · filed 2016-05-13 | $430.65K derived: sum of 2 quarters · filed 2016-05-13 | $542.25K derived: sum of 3 quarters · filed 2016-05-13 | $634.69K derived: sum of 4 quarters · filed 2016-05-13 | |||
| 2014-12-31 | $109.21K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $220.81K derived: sum of 2 quarters · filed 2016-03-30 | $313.25K derived: sum of 3 quarters · filed 2016-03-30 | $531.12K 10-K · filed 2016-03-30 | |||
| 2014-09-30 | $111.60K 10-Q · filed 2015-11-12 | $204.03K derived: sum of 2 quarters · filed 2015-11-12 | $421.90K 10-Q · filed 2015-11-12 | ||||
| 2014-06-30 | $92.44K 10-Q · filed 2015-08-12 | $310.30K 10-Q · filed 2015-08-12 | |||||
| 2014-03-31 | $217.87K 10-Q · filed 2015-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |